Testicular seminoma: Are clinical features and treatment outcomes any different in India?

Anjanappa, Milan; Kumar, Aswin; Mathews, Susan; Joseph, John; Jagathnathkrishna, Krishnapillai M.; James, Francis V.

doi:10.4103/ijc.ijc_100_17

Cited by 3 publications

(3 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The incidence is less when compared to previously published Indian data, where 12.5% of tumours developed in the undescended testis [11]. The incidence of undescended testis in our part of the world is probably decreasing, as seen from our previous publications [12,13]. Presence of LVSI is considered as an independent prognostic factor for recurrence in stage I nonseminomatous tumours [14], but due to the limited data on LVSI, it was not assessed in this study.…”

Section: Discussionmentioning

confidence: 61%

Prognostic factors and outcomes of nonseminomatous germ cell tumours of testis—experience from a tertiary cancer centre in India

Nair¹,

Krishna²,

Kumar³

et al. 2020

ecancer

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 61%

Prognostic factors and outcomes of nonseminomatous germ cell tumours of testis—experience from a tertiary cancer centre in India

Nair¹,

Krishna²,

Kumar³

et al. 2020

ecancer

View full text Add to dashboard Cite

“…Testicular cancers (TC) constitute 1% of cancers in males worldwide (1,2). Besides, they represent 5% of urological tumors (3).…”

Section: Introductionmentioning

confidence: 99%

“…The rate of complete cure is approximately 100% (8). The treatment options to be performed following orchiectomy may vary depending on pathological diagnosis, stage and risk factors (2).…”

Section: Introductionmentioning

confidence: 99%

Testiküler Seminomatöz ve Nonseminomatöz Germ Hücreli Tümörler: Klinik ve Patolojik Özelliklerinin Karşılaştırılması

Gürsoy¹,

Seçinti²,

Gökalp³

et al. 2021

Mustafa Kemal Üniversitesi Tıp Dergisi

View full text Add to dashboard Cite

Objective: In the present study, it was aimed to investigate the differences between the clinical and histopathological features of testicular seminomatous and non-seminomatous germ cell tumors diagnosed in our center in the recent 10 years. Methods: All the patients in whom diagnosis of testicular germ cell tumor was histologically confirmed in our center between January 2010 and May 2020 were involved in the study. The medical records of the patients were screened and Hematoxylin-Eosin (H+E) stained slides of the patients were re-evaluated. The tumor classification and primary tumor stage determination (pT) were carried out in accordance with the 2016 WHO Classification of Tumors of the Urinary System and Male Genital Organs. Results:The morphology of seminoma (SEM) and non-seminomatous germ cell tumors (NSE-GCTs) were identified in 27 (51%) and 26 (49%) of the study patients, respectively. In the SEM group, patient ages ranged between 23-55 years (min-max) and median age was 33 years (IQR=26.0-41.0) while those values for the NSE-GCT cases were 16-44 years and 28 years (IQR=22.75-29.5), respectively. The evaluation of the pTs without subgroup discrimination demonstrated that 21 (39.6%), 31 (58.5%) and 1 (1.9%) of the tumors were Stage 1, Stage 2 and Stage 3, respectively. Conclusion: Testicular cancers are the most frequently seen malignancy in the young males and its incidence has increased in the recent years. The complete cure rate is approximately 100% thanks to early diagnosis as well as high chemosensitivity and radiosensitivity of these tumors.

show abstract

The core four - A panel of immunohistochemistry markers to diagnose and subtype testicular germ cell tumors

et al. 2022

View full text Add to dashboard Cite

Context: Immunohistochemistry (IHC) to differentiate germ cell tumors. Aims: The aim of the study is to differentiate seminomatous and nonseminomatous germ cell tumors (GCTs) with morphological overlap using a minimal and affordable panel of IHC markers. Settings and Design: This is a retrospective observational study. Subjects and Methods: All testicular GCTs (TGCT) which were diagnosed on biopsies and/or resection specimens (prechemotherapy) between January 2014 and June 2019. The demographic, clinical, and imaging findings were noted from the medical records. Hematoxylin and eosin (H and E)-stained sections were reviewed for morphology. The IHC markers constituted Octamer-binding transcription factor (OCT) 3/4, glypican 3 (GPC3), CD117, CD30, placental-like alkaline phosphatase, Sal-like protein 4, and β-human chorionic gonadotropin (HCG). IHC markers were performed in various combinations depending on the morphology, and a panel constituting OCT 3/4, CD117, GPC3, and CD30 was performed on cases with diagnostic dilemma and morphological overlaps. Statistical Analysis Used: Sensitivity, specificity, positive (PPV), and negative predictive value (NPV) were calculated for suggested panel of IHC OCT 3/4, CD117, GPC3, and CD30. Results: The study included 36 patients with TGCT with a mean age of 27 (15–58) years. Nonseminomatous tumors were the most common (86%). The concise panel was performed in 20/36 (56%) tumors to resolve the diagnosis. The sensitivity, specificity, PPV, and NPV for OCT3/4 were 80%, 55%, 31%, and 92% in seminomas and 65%, 100%, 100%, and 46% in embryonal carcinomas (EC), for CD117 was 89%, 82%, 73%, and 93% in seminomas and 60%, 77%, 60%, and 77% in yolk sac tumors (YST), for GPC3 was 95%, 90%, 95%, and 90% in YST, CD30 96%, 100%, 100%, and 91% in ECs, respectively. Conclusions: Designing a novel concise and affordable IHC panel constituting OCT 3/4, CD117, GPC3, and CD30 has good sensitivity and specificity in differentiating seminomas, YST, and EC, respectively. Additional markers, namely β-HCG, can be used in identifying the choriocarcinoma component.

show abstract

Testicular seminoma: Are clinical features and treatment outcomes any different in India?

Cited by 3 publications

References 13 publications

Prognostic factors and outcomes of nonseminomatous germ cell tumours of testis—experience from a tertiary cancer centre in India

Prognostic factors and outcomes of nonseminomatous germ cell tumours of testis—experience from a tertiary cancer centre in India

Testiküler Seminomatöz ve Nonseminomatöz Germ Hücreli Tümörler: Klinik ve Patolojik Özelliklerinin Karşılaştırılması

The core four - A panel of immunohistochemistry markers to diagnose and subtype testicular germ cell tumors

Contact Info

Product

Resources

About